← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
INTEGRA LIFESCIENCES HOLDINGS CORP: Revenue grew 1.5% to $1.635B from $1.611B. The net loss widened from $6.944M to $516.474M. Free cash flow turned negative at an outflow of $31.052M from $24.964M. Operating margin contracted 3193 bps to -30.17%. INTEGRA LIFESCIENCES HOLDINGS CORP's annual comparison also shows free cash flow declined despite revenue growth; inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 1.5%OK
- Profitability — The net loss widened from $6.944M to $516.474MWatch
- Cash flow — Free cash flow turned negative at an outflow of $31.052M from $24.964MWatch
- Margins — Operating margin contracted 3193 bps to -30.17%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 1 purchases and 0 salesOK
Business
Our research and development efforts are focused on the further development and improvement of our existing products, the design and development of new innovative medical technologies and regulatory compliance across all our business segments.
Where the revenue comes from
Fiscal 2025, as INTEGRA LIFESCIENCES HOLDINGS CORP reports it. History and quarterly detail are in the app.
- Codman Specialty Surgical$1.2B
- Tissue Technologies$434.7M
Leadership changes
From INTEGRA LIFESCIENCES HOLDINGS CORP's own filings, the day they're filed.
- Mojdeh Poul · Chief Executive Officer · departureeff. 2026-05-01
- Jan De Witte · President · appointmenteff. 2024-02-27
- Stuart M. Essig · Chairman · appointmenteff. 2024-02-27
Latest filings
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about INTEGRA LIFESCIENCES HOLDINGS CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.